Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Feasibility study of Neo-adjuvant (before surgery) versus Adjuvant (after surgery) chemotherapy in Upper Tract Urothelial Carcinoma Under evaluation

2024-514991-41-01 Upper Tract Urothelial Carcinoma. Upper urinary tract t 4
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors Under evaluation

2025-524192-24-00 advanced refractory solid tumors 1
A Study of Disitamab Vedotin Alone and with Pembrolizumab in Urothelial Cancer That Expresses HER2 Not authorised

2022-500030-28-00 Urothelial carcinoma 4
Dose expansion, safety and efficacy study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder can… Not authorised

2023-505062-28-00 Non-muscle invasive bladder cancer 9
A Phase I Clinical Trial of CART cell therapy for refractory/ relapsed acute lymphoblastic leukemia with unmet needs in children, adolescent… Not authorised

2023-509723-41-00 Refractory/ relapsed acute lymphoblastic leukemia in ch 3
Pressurized intrathoracic aerosol chemotherapy (PITAC) in patients with malignant pleural effusion: a single-center phase II trial. PITAC_ M… Not authorised

2024-511255-17-00 Pleural carcinosis 4
LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination with Investigational Ag… Not authorised

2023-507179-23-00 Hematologic Malignancies or Solid Tumors in Pediatric a 9
KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer Not authorised

2022-501854-12-00 KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma 1
A study to investigate WEF-001 in patients with Advanced KRAS-Mutant Solid Tumours. Not authorised

2024-518644-21-00 Advanced KRAS- Mutant Solid Tumours 9
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised

2023-506686-66-00 HLA-A2 negative metastatic uveal melanoma 10
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochem… Not authorised

2023-504066-39-00 Prostate Cancer 7
Impact of time of alpelisib administration, concomitant fasting and low carbohydrate diet on alpelisib toxicity and efficacy; a pilot random… Not authorised

2025-521008-22-00 metasatic breast cancer, hormon positive, her 2 negativ 4
MELFLUFEN FOR ELDERLY PATIENTS WITH RELAPSED MYELOMA Not authorised

2024-514652-33-00 Relapsed Multiple Myeloma 4
A phase 2 study to research the safety and efficacy of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with acti… Not authorised

2024-512369-14-00 Non-small cell lung cancer (NSCLC). 4
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Po… Not authorised

2025-521052-35-00 Patients with HER2Positive Advanced Breast Cancer 7
ITP BLOCK FOR MINOR BREAST CANCER SURGERY Not authorised

2022-501312-34-00 Breast cancer 6
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors Not authorised

2024-519862-33-00 Platinum-resistant ovarian cancer (PROC) 1
[68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic canc… Not authorised

2023-503632-41-00 Pancreatic cancer and gastroesophageal cancer (esophagu 4
Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI… Not authorised

2024-514693-47-00 EGFR mutated locally advanced or metastatic non-small c 11
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised

2023-509861-19-00 Diffuse large B-cell lymphoma (DLBCL) 4
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr… Not authorised

2024-512403-39-00 Advanced Solid Tumors Who Are Beyond Standard of Care 1
CRISPR-TIL for metastatic melanoma Not authorised

2023-510417-25-00 Advanced or metastatic melanoma 1
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Not authorised

2023-504231-41-00 Locally advanced or metastatic urothelial cancer 10
Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc… Not authorised

2024-515603-19-00 Localized digestive Neuroendocrine Carcinomas 4